Reviews in Medical Virology最新文献

筛选
英文 中文
Could Delayed Primary Epstein-Barr Virus Infection Contribute to the Rising Incidence of Type 1 Diabetes? 延迟原发性eb病毒感染是否会导致1型糖尿病发病率上升?
IF 5.5 2区 医学
Reviews in Medical Virology Pub Date : 2026-11-01 DOI: 10.1002/rmv.70226
Cyril Debuysschere, Mahdi Ouafi, Magloire Pandoua Nekoua, Enagnon Kazali Alidjinou, Didier Hober
{"title":"Could Delayed Primary Epstein-Barr Virus Infection Contribute to the Rising Incidence of Type 1 Diabetes?","authors":"Cyril Debuysschere, Mahdi Ouafi, Magloire Pandoua Nekoua, Enagnon Kazali Alidjinou, Didier Hober","doi":"10.1002/rmv.70226","DOIUrl":"10.1002/rmv.70226","url":null,"abstract":"<p><p>Type 1 diabetes mellitus (T1DM) incidence has been rising for several decades and varies markedly across countries, a pace and geographical spread that genetic susceptibility alone cannot explain, pointing to a major role for environmental factors. Viruses have long been regarded as triggers of islet autoimmunity, yet recent clinical and experimental observations suggest that Epstein-Barr virus (EBV) may instead exert immunoregulatory effects that could protect against islet autoimmunity. EBV establishes a lifelong infection in approximately 95% of adults worldwide in memory B cells, generally during the first years of life, but the age at primary infection has shifted progressively towards adolescence in high-income countries, reflecting improved hygiene standards. This review compares the age at primary EBV infection with T1DM incidence across regions and populations that differ in hygiene standards and cultural practices. Populations in which primary infection occurs in early childhood generally show a low incidence of T1DM and a high incidence of nasopharyngeal carcinoma (NPC), an EBV-induced cancer, whereas the opposite pattern is observed in some populations in which primary infection is delayed; comparable contrasts are found between ethnic groups living within the same country. Delayed exposure to EBV, a virus that has coevolved with the human lineage over millions of years and for which protective effects against islet autoimmunity have been proposed, may therefore contribute, alongside other environmental determinants, to the rising incidence of T1DM, potentially extending the 'Old friends' hypothesis to a common virus belonging to the Orthoherpesviridae family.</p>","PeriodicalId":21180,"journal":{"name":"Reviews in Medical Virology","volume":"36 6","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13750830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149387670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Local Delivery of Interferon-β1a for Respiratory Viral Infections: A Systematic Review. 局部递送干扰素β1a治疗呼吸道病毒感染:系统综述。
IF 5.5 2区 医学
Reviews in Medical Virology Pub Date : 2026-11-01 DOI: 10.1002/rmv.70208
Mahsa Nayebhashemi, Mandana Akhavan, Aryan Foroohari, Sorousha Khayat, Khashayar Roshanzamir, Maryam Shafaati, Mohammadreza Salehi
{"title":"Local Delivery of Interferon-β1a for Respiratory Viral Infections: A Systematic Review.","authors":"Mahsa Nayebhashemi, Mandana Akhavan, Aryan Foroohari, Sorousha Khayat, Khashayar Roshanzamir, Maryam Shafaati, Mohammadreza Salehi","doi":"10.1002/rmv.70208","DOIUrl":"10.1002/rmv.70208","url":null,"abstract":"<p><p>Respiratory viral infections represent a major global health burden, with impaired antiviral interferon responses contributing to disease progression in several respiratory conditions. This systematic review evaluated the efficacy, safety, and biological effects of locally delivered intranasal or inhaled interferon-β1a (IFN-β1a), a host-directed antiviral therapy, across prophylactic, therapeutic, and experimental models of respiratory viral infections. A systematic review was conducted according to PRISMA 2020 guidelines by searching PubMed, Embase, Scopus, Web of Science, Google Scholar, patent databases, and ClinicalTrials.gov up to July 2025. Peer-reviewed clinical and experimental studies, as well as relevant patent records, were identified. Patent and grey-literature sources were examined to provide a comprehensive overview of the development of locally delivered IFN-β1a and to identify relevant technological approaches that might not be captured in conventional bibliographic databases; however, these records were not considered evidence of clinical efficacy or safety. Eligible clinical and experimental evidence included randomized controlled trials (RCTs), in vitro, and in vivo studies. Owing to substantial clinical and methodological heterogeneity, findings were synthesised using a structured narrative and stratified approach rather than quantitative pooling. Risk of bias was assessed using RoB 2 for RCTs, ToxRTool for in vitro studies, and the SYRCLE tool for in vivo studies. Twenty-four studies met the inclusion criteria, including 12 RCTs, seven in vitro studies, one in vivo study, and four patent reports. Preclinical evidence consistently demonstrated antiviral and immunomodulatory activity, including reduced viral replication and induction of interferon-stimulated genes. Clinical studies demonstrated consistent antiviral activity and immune modulation (e.g., ISG upregulation, viral load reduction). However, clinically meaningful benefit varied across populations and was most consistent in asthma, COPD, and hospitalised COVID-19 patients, whereas other trials did not demonstrate significant improvements in their primary clinical outcomes. Early prophylactic studies in rhinovirus infection showed limited and inconsistent clinical preventive efficacy despite detectable antiviral activity. Pharmacokinetic studies supported effective airway delivery, while safety findings indicated generally favourable tolerability with predominantly mild, transient adverse events. Available evidence indicates that intranasal or inhaled IFN-β may enhance antiviral immunity and provide clinical benefit in selected respiratory viral conditions, particularly among individuals with impaired antiviral responses. However, evidence for prophylactic efficacy against community-acquired upper respiratory tract infections remains limited, and further studies are required to define optimal indications, dosing strategies, and target populations.</p>","PeriodicalId":21180,"journal":{"name":"Reviews in Medical Virology","volume":"36 6","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149272916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mapping the Evidence for Oropouche Virus to Inform Research Prioritisation. 绘制Oropouche病毒的证据以确定研究重点。
IF 5.5 2区 医学
Reviews in Medical Virology Pub Date : 2026-11-01 DOI: 10.1002/rmv.70222
Sowsan F Atabani, Matthew Bosworth, Amy Bobbins, Beti Evans, Zalaya Simmons, Nicola Pearce-Smith, Julia A Tree, Charles Dearman, Yper Hall, Daphne Duval
{"title":"Mapping the Evidence for Oropouche Virus to Inform Research Prioritisation.","authors":"Sowsan F Atabani, Matthew Bosworth, Amy Bobbins, Beti Evans, Zalaya Simmons, Nicola Pearce-Smith, Julia A Tree, Charles Dearman, Yper Hall, Daphne Duval","doi":"10.1002/rmv.70222","DOIUrl":"10.1002/rmv.70222","url":null,"abstract":"<p><p>Oropouche virus (OROV) infection has gained increasing public health attention due to the ongoing outbreaks in South and Central America. The World Health Organisation (WHO) lists OROV as a priority pathogen for epidemic and pandemic preparedness. This work aimed to identify and categorise the available evidence on OROV to inform research prioritisation. We conducted a rapid mapping review (search date: up to 5 June 2025) to identify primary studies on OROV and categorised these by area of research, study design, and geographic region using a pre-defined framework. Included studies were displayed in an interactive evidence gap map (EGM) to identify any evidence gaps. In total, 269 primary studies on OROV were included and mapped into the EGM. Of these, the majority of data and findings were reported from South America, Central America and the Caribbean, reflecting the geographical epidemiology of OROV. The majority of studies were observational and descriptive, based on specific outbreaks. Limited evidence was found on vector surveillance, viral pathogenesis, diagnostics and immune correlates of protection. No experimental studies on potential therapeutics or vaccines conducted in humans were identified. The findings from our mapping review and EGM highlight the utility of this methodology to rapidly identify gaps in scientific evidence for emerging or re-emerging pathogens with outbreak potential. The EGM can be used solely, or in conjunction with other prioritisation tools, in order to focus investment and research efforts towards priority topics.</p>","PeriodicalId":21180,"journal":{"name":"Reviews in Medical Virology","volume":"36 6","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13695555/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149272894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evidence Synthesis Guidance for Reviews in Medical Virology. 医学病毒学综述的证据综合指南。
IF 5.5 2区 医学
Reviews in Medical Virology Pub Date : 2026-11-01 DOI: 10.1002/rmv.70224
Amin Sharifan, Daniele Focosi
{"title":"Evidence Synthesis Guidance for Reviews in Medical Virology.","authors":"Amin Sharifan, Daniele Focosi","doi":"10.1002/rmv.70224","DOIUrl":"10.1002/rmv.70224","url":null,"abstract":"<p><p>There is substantial variability in how reviews are conducted and reported within the medical literature. Authors submitting manuscripts to Reviews in Medical Virology are encouraged to follow the best practices outlined in this editorial.</p>","PeriodicalId":21180,"journal":{"name":"Reviews in Medical Virology","volume":"36 6","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149387671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Human Cytomegalovirus Genetic Diversity, Clinical Relevance, and Emerging Insights. 人类巨细胞病毒遗传多样性,临床相关性和新兴见解。
IF 5.5 2区 医学
Reviews in Medical Virology Pub Date : 2026-09-01 DOI: 10.1002/rmv.70197
Hajar Y AlQahtani, Fadilah Sfouq Aleanizy, Fulwah Yahya Alqahtani
{"title":"Human Cytomegalovirus Genetic Diversity, Clinical Relevance, and Emerging Insights.","authors":"Hajar Y AlQahtani, Fadilah Sfouq Aleanizy, Fulwah Yahya Alqahtani","doi":"10.1002/rmv.70197","DOIUrl":"10.1002/rmv.70197","url":null,"abstract":"<p><p>Human cytomegalovirus (HCMV) is a globally prevalent virus that poses a significant public health concern, especially for newborns and immunocompromised patients, causing a wide range of infections. Clinical outcomes associated with HCMV infection include congenital disease, graft rejection in transplant recipients, and life-threatening systemic infections with significant morbidity and mortality. HCMV is a member of the Beta-herpesvirinae subfamily. Distinguishing characteristics of HCMV, in particular, and herpesviruses in general are their ubiquitous presence in nature and the initial infection that often results in lifelong latency. Over the past 40 years, the genetics of HCMV have been explored, leading to the isolation of various genotypes, including those of glycoprotein B, glycoprotein N, and UL144. Despite operational obstacles in isolating HCMV genotypes due to heterogeneity in the technologies used for genotyping the virus, studies have been able to describe their clinical implications across a variety of human hosts. This review summarises the genotypic variation of HCMV and discusses its clinical relevance and impact on antiviral resistance and vaccine development. Understanding the genetic diversity of HCMV genotypes is crucial for advancing drug development to combat resistant strains and for developing new vaccines and treatment modalities.</p>","PeriodicalId":21180,"journal":{"name":"Reviews in Medical Virology","volume":"36 5","pages":"e70197"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13524432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148851450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epitranscriptomic Regulation in Oncogenic Viruses: Emerging Roles of RNA Modifications in Viral Persistence and Tumourigenesis. 致癌病毒的表转录组调控:RNA修饰在病毒持久性和肿瘤发生中的新作用。
IF 5.5 2区 医学
Reviews in Medical Virology Pub Date : 2026-09-01 DOI: 10.1002/rmv.70204
Zinan Yang, Yang Bai, Lihui Jia, Ying Zhang, Qiang Sun
{"title":"Epitranscriptomic Regulation in Oncogenic Viruses: Emerging Roles of RNA Modifications in Viral Persistence and Tumourigenesis.","authors":"Zinan Yang, Yang Bai, Lihui Jia, Ying Zhang, Qiang Sun","doi":"10.1002/rmv.70204","DOIUrl":"https://doi.org/10.1002/rmv.70204","url":null,"abstract":"<p><p>Oncogenic viral pathogens, such as human papillomavirus (HPV), Epstein-Barr virus (EBV), hepatitis B and C viruses (HBV, HCV), and Kaposi's sarcoma-associated herpesvirus (KSHV), are involved in a significant proportion of human cancers worldwide. While genetic and epigenetic mechanisms underlying viral oncogenesis have been thoroughly investigated, emerging evidence underscores a critical role for epitranscriptomic regulation in virus-host interactions and their clinical consequences. RNA modifications such as N6-methyladenosine (m6A), 5-methylcytosine (m5C), and pseudouridine (Ψ) dynamically modulate RNA stability, translation, and immune recognition, thereby regulating viral replication and persistence. The present review describes current knowledge on the epitranscriptomic landscape of oncogenic viral pathogens and its functional implications. This review discusses how viral and host transcripts are selectively modified by cellular writers, erasers, and readers, shaping key stages of the viral life cycle, including replication, latency, and reactivation. Particular emphasis is placed on the role of RNA modifications in maintaining chronic infection and promoting tumourigenesis through the regulation of oncogenic pathways, cell proliferation, and apoptosis. Additionally, the present review examines how epitranscriptomic marks contribute to immune evasion by altering innate immune sensing and interferon responses. Finally, it explores the therapeutic potential of targeting epitranscriptomic machinery, highlighting recent advances in small-molecule inhibitors and the challenges associated with specificity and off-target effects. A deeper understanding of epitranscriptomic regulation in oncogenic viruses may reveal novel biomarkers and therapeutic strategies for virus-linked malignancies.</p>","PeriodicalId":21180,"journal":{"name":"Reviews in Medical Virology","volume":"36 5","pages":"e70204"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149008902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Appraisal of the Potential Downstream Benefits of RSV Vaccination in Older Adults. 老年人RSV疫苗潜在下游益处的评估
IF 5.5 2区 医学
Reviews in Medical Virology Pub Date : 2026-09-01 DOI: 10.1002/rmv.70198
Piotr Rzymski
{"title":"An Appraisal of the Potential Downstream Benefits of RSV Vaccination in Older Adults.","authors":"Piotr Rzymski","doi":"10.1002/rmv.70198","DOIUrl":"10.1002/rmv.70198","url":null,"abstract":"<p><p>Respiratory syncytial virus (RSV) has long been underrecognized as a significant pathogen in older adults, despite accumulating evidence of its substantial morbidity and mortality burden in this population. While RSV vaccination is now well established as an effective intervention for preventing lower respiratory tract disease, this narrative review examines whether its public health value may extend beyond these primary clinical endpoints. A targeted search of Scopus and Web of Science from database inception to May 2026 was conducted to identify biological, epidemiological, observational, interventional, and modelling evidence relevant to potential downstream vaccine effects. The available evidence potentially supports hypotheses concerning possible reductions in cardiovascular complications and secondary bacterial infections, possible decreases in transmission to younger household contacts, and potential preservation of functional status and independence. However, the strength of evidence varies substantially across these outcomes. Cardiovascular protection has not been independently demonstrated in randomized trials, bacterial and antimicrobial-use outcomes have rarely been prespecified, real-world household transmission studies are unavailable, and functional trajectories may be strongly modified by baseline frailty and pre-existing disability. RSV vaccination in older adults therefore remains a well-validated strategy for preventing acute respiratory disease, whereas its proposed broader effects should be regarded as biologically plausible but incompletely demonstrated benefits. Future studies should incorporate prespecified cardiovascular, bacterial, transmission, geriatric, and functional outcomes, with particular attention to frailty, antimicrobial use, and longer-term follow-up.</p>","PeriodicalId":21180,"journal":{"name":"Reviews in Medical Virology","volume":"36 5","pages":"e70198"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13532495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148866049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gut Microbiota Alterations in People Living With HIV: Dysbiosis, Immune Dysfunction and Therapeutic Perspectives. HIV感染者肠道菌群的改变:生态失调、免疫功能障碍和治疗前景。
IF 5.5 2区 医学
Reviews in Medical Virology Pub Date : 2026-09-01 DOI: 10.1002/rmv.70202
Soukaina El Mheddeb, Assiya El Kettani, Ahmed Aziz Bousfiha, Sayeh Ezzikouri, Ahd Ouladlahsen
{"title":"Gut Microbiota Alterations in People Living With HIV: Dysbiosis, Immune Dysfunction and Therapeutic Perspectives.","authors":"Soukaina El Mheddeb, Assiya El Kettani, Ahmed Aziz Bousfiha, Sayeh Ezzikouri, Ahd Ouladlahsen","doi":"10.1002/rmv.70202","DOIUrl":"10.1002/rmv.70202","url":null,"abstract":"<p><p>The interaction between the human immunodeficiency virus (HIV) and the gut microbiota is attracting growing interest due to its potential role in the progression of infection and the development of comorbidities. This review provides a comprehensive and critically appraised synthesis of current evidence on the bidirectional relationship between HIV infection and gut microbiota disruption, structured around four central themes: the mechanistic basis of HIV-associated gut dysbiosis and mucosal immune dysfunction and its link to chronic inflammation; the effects of different antiretroviral therapy (ART) classes on the intestinal ecosystem; the emerging role of the microbiota-gut-brain axis in the pathogenesis of HIV-associated neurocognitive disorders (HAND); and the therapeutic potential of microbiota-targeted interventions, including probiotics, prebiotics, synbiotics, faecal microbiota transplantation (FMT), and dietary strategies in people living with HIV (PLWH). By synthesising the current mechanistic, clinical, and translational evidence, this review aims to delineate the critical knowledge gaps and define the research priorities that will drive the next generation of microbiota-informed strategies for improving long-term outcomes in PLWH. This summary highlights the importance of considering the gut microbiota as a key player in the overall management of HIV infection.</p>","PeriodicalId":21180,"journal":{"name":"Reviews in Medical Virology","volume":"36 5","pages":"e70202"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13581345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148983546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CRISPR-Engineered CAR-T Cell Therapy for Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma: A Review of Emerging Therapeutic Prospects. crispr工程CAR-T细胞治疗eb病毒相关鼻咽癌:新兴治疗前景综述
IF 5.5 2区 医学
Reviews in Medical Virology Pub Date : 2026-09-01 DOI: 10.1002/rmv.70199
Noor Allehyani, Mohammed Alissa, Abdullah Alghamdi, Mohammed A Alshehri, Ghadah S Abusalim, Alaa S Alhegaili, Tawfiq N Juraybi, Meshari A Alsuwat
{"title":"CRISPR-Engineered CAR-T Cell Therapy for Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma: A Review of Emerging Therapeutic Prospects.","authors":"Noor Allehyani, Mohammed Alissa, Abdullah Alghamdi, Mohammed A Alshehri, Ghadah S Abusalim, Alaa S Alhegaili, Tawfiq N Juraybi, Meshari A Alsuwat","doi":"10.1002/rmv.70199","DOIUrl":"10.1002/rmv.70199","url":null,"abstract":"<p><p>Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC) remains a clinically challenging malignancy, particularly in recurrent or metastatic disease where durable responses to chemoradiotherapy and immune checkpoint blockade are limited. The viral aetiology of NPC provides a strong biological rationale for immune-based treatment; however, translation of chimaeric antigen receptor (CAR) T-cell therapy into this solid tumour setting is constrained by poor tumour trafficking, antigen heterogeneity, limited surface accessibility of EBV latent antigens, T-cell exhaustion, and an immunosuppressive tumour microenvironment. This review critically evaluates the emerging therapeutic prospects of CRISPR-engineered CAR-T cell therapy for EBV-associated NPC. It synthesises evidence on EBV latency biology, NPC immune evasion, solid-tumour CAR-T limitations, and genome-engineering strategies including conventional CRISPR-Cas9, base editing, prime editing, and double-strand-break-sparing targeted integration. Particular attention is given to genotoxicity, chromosomal rearrangements, chromosome loss, bystander and off-target editing, manufacturing heterogeneity, and the regulatory and biological barriers that currently separate technical feasibility from NPC-specific clinical implementation. Available clinical evidence from checkpoint blockade, EBV-specific adoptive T-cell therapy, base-edited CAR-T cells in haematologic malignancy, and early CRISPR-edited T-cell trials supports the feasibility of immune and genetic redirection but does not establish efficacy of a clinically validated CRISPR-engineered CAR-T platform for NPC. Future development should prioritise surface-accessible antigen validation, fit-for-purpose selection of editing technology, genomic safety, scalable manufacturing, and biomarker-driven early-phase trials.</p>","PeriodicalId":21180,"journal":{"name":"Reviews in Medical Virology","volume":"36 5","pages":"e70199"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13546091/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148897820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Effectiveness of the Recombinant Zoster Vaccine Against Herpes Zoster, Herpes Zoster Ophthalmicus, Postherpetic Neuralgia and Dementia: A Systematic Review and Meta-Analysis. 重组带状疱疹疫苗预防带状疱疹、带状疱疹眼炎、带状疱疹后神经痛和痴呆的疗效和效果:系统综述和荟萃分析
IF 5.5 2区 医学
Reviews in Medical Virology Pub Date : 2026-09-01 DOI: 10.1002/rmv.70203
E Heen, J Øverbø, I H Tveteraas, S L Solberg, H Nøkleby, J E Midtbø, F Di Rusco, F Kasteng, A Ersson, S Andersson, K Johansen, L K Juvet
{"title":"Efficacy and Effectiveness of the Recombinant Zoster Vaccine Against Herpes Zoster, Herpes Zoster Ophthalmicus, Postherpetic Neuralgia and Dementia: A Systematic Review and Meta-Analysis.","authors":"E Heen, J Øverbø, I H Tveteraas, S L Solberg, H Nøkleby, J E Midtbø, F Di Rusco, F Kasteng, A Ersson, S Andersson, K Johansen, L K Juvet","doi":"10.1002/rmv.70203","DOIUrl":"10.1002/rmv.70203","url":null,"abstract":"<p><p>Herpes zoster (HZ, shingles) constitutes a significant public health concern, particularly in ageing populations, and there is growing global interest in the recombinant zoster vaccine (RZV) from a public health perspective. In this systematic review with meta-analysis, we assessed the efficacy and effectiveness of RZV against HZ and its complications, including a possible association with a reduced risk of dementia, among immunocompetent individuals aged 50 years and older. We synthesised the latest evidence on long-term effects, incorporating recent data from both trials and real-world effectiveness studies. A total of 27 publications based on 18 primary studies, 3 randomised controlled trials (RCTs) and 15 observational studies, were included. RZV provides very high protection against HZ in immunocompetent adults ≥ 50 years in RCTs, with approximately 95% efficacy and high certainty of evidence (CoE) according to GRADE. Observational studies also consistently indicate substantial protection, but effect estimates vary across settings (high CoE). Among vaccinated individuals who develop HZ, RZV is associated with reduced loss of quality of life and decreased analgesic use. The vaccine also substantially reduces the risk of herpes zoster ophthalmicus (HZO) (high CoE) and likely postherpetic neuralgia (PHN) (moderate CoE). Long-term follow-up suggests durable protection for at least 11 years (low CoE). RZV may be associated with a reduced risk of dementia (low CoE), due to uncertainty the true effect may be substantially different, and similar associations have been observed with other vaccines and may be confounded by healthy vaccinee bias.</p>","PeriodicalId":21180,"journal":{"name":"Reviews in Medical Virology","volume":"36 5","pages":"e70203"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13581344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148983513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书